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Abstract
Acute Lung Injury (ALI) is a syndrome with high associated mortality characterized by severe hypoxemia and pulmonary
infiltrates in patients with critical illness. We conducted the first investigation to use the genome wide association (GWA)
approach to identify putative risk variants for ALI. Genome wide genotyping was performed using the Illumina Human Quad
610 BeadChip. We performed a two-stage GWA study followed by a third stage of functional characterization. In the
discovery phase (Phase 1), we compared 600 European American trauma-associated ALI cases with 2266 European
American population-based controls. We carried forward the top 1% of single nucleotide polymorphisms (SNPs) at p,0.01
to a replication phase (Phase 2) comprised of a nested case-control design sample of 212 trauma-associated ALI cases and
283 at-risk trauma non-ALI controls from ongoing cohort studies. SNPs that replicated at the 0.05 level in Phase 2 were
subject to functional validation (Phase 3) using expression quantitative trait loci (eQTL) analyses in stimulated B-
lymphoblastoid cell lines (B-LCL) in family trios. 159 SNPs from the discovery phase replicated in Phase 2, including loci with
prior evidence for a role in ALI pathogenesis. Functional evaluation of these replicated SNPs revealed rs471931 on 11q13.3
to exert a cis-regulatory effect on mRNA expression in the PPFIA1 gene (p=0.0021). PPFIA1 encodes liprin alpha, a protein
involved in cell adhesion, integrin expression, and cell-matrix interactions. This study supports the feasibility of future multi-
center GWA investigations of ALI risk, and identifies PPFIA1 as a potential functional candidate ALI risk gene for future
research.
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Introduction
Acute lung injury (ALI) is a syndrome characterized by diffuse
pulmonary edema and severe hypoxemia in the absence of clinical
evidence of left atrial hypertension [1]. ALI affects an estimated
190,000 people annually in the United States and carries a
mortality of over 35% [2]. Because only a proportion of patients
exposed to predisposing conditions develop ALI (e.g. following
sepsis, pneumonia, aspiration, or trauma), it has been hypothe-
sized that individual genetic variation may contribute to the
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e28268observed variability in ALI susceptibility [3,4]. Prior studies of
genetics of ALI using candidate gene approaches have identified
variation in genes controlling inflammation, apoptosis, oxidative
stress, or endothelial permeability among others that may confer
differential risk of developing ALI [5,6,7,8,9,10,11,12,13,14,15].
adding to evidence that risk of developing ALI may have a genetic
basis.
Genome-wide association studies (GWAS) are powerful,
unbiased tools for the identification of common genetic variants,
e.g., single nucleotide polymorphisms (SNPs), associated with
complex traits [16]. Despite potential limitations [17], GWAS
have led to the identification of genetic susceptibility loci that
reproducibly confer risk for complex diseases such as Crohn’s
disease, rheumatoid arthritis, and Type II diabetes [16,18,19]. To
date, the GWAS approach has not been applied to the study of
ALI.
We report the first GWAS of ALI susceptibility, using a three
stage approach, including a discovery phase, a replication phase,
and a functional evaluation phase using gene expression screening
in family trios. We hypothesized that a GWAS approach would
identify common genetic variants associated with a reproducible
differential risk of ALI.
Methods
This study was approved by the institutional review boards
(IRBs) of the Children’s Hospital of Philadelphia (CHOP), the
University of Pennsylvania School of Medicine, University of
Washington, Harvard School of Public Health, Vanderbilt
University, and the University of California at San Francisco.
Study Populations
We chose an at-risk trauma population to minimize heteroge-
neity from multiple precipitating factors of ALI and to efficiently
allow for comparison with population-based controls, as major
trauma is largely a stochastic event across populations. ALI cases
and at-risk controls were identified from severe trauma cohort
studies performed at 5 U.S. centers: Harvard University/
Massachusetts General Hospital, University of Pennsylvania,
Vanderbilt University, University of Washington, and University
of California at San Francisco. Entry criteria were an Injury
Severity Score (ISS) $16 and admission through the Emergency
department to an intensive care unit. ALI was defined accord-
ing to American European Consensus Conference (AECC)
criteria [20] by trained investigators at each site [13,14,21,
22,23,24,25,26]. Written informed consent was obtained from
participants at Harvard University/Massachusetts General Hos-
pital, Vanderbilt University, University of Washington, and
University of California at San Francisco. Participants at
University of Pennsylvania were collected under a waiver of
consent granted by the University of Pennsylvania IRB.
Population-based controls were recruited from ongoing cohorts
at the Center for Applied Genomics at CHOP [27,28].
Study Design
We performed a two-stage genotyping strategy [29], with a third
stage of functional characterization (Figure 1). In the discovery
phase (Phase 1), we compared 600 European American trauma-
associated ALI cases with 2266 European American population-
based pediatric healthy controls taken from ongoing studies at
Children’s Hospital of Philadelphia (CHOP). Pediatric population
controls [27,28] were chosen for the discovery phase to maximize
efficiency and cost savings [30] for the following reasons: these
controls were available in large number and had been genotyped
on the same genome-wide platform during a similar time; ALI is
not a chronic disease, there is no known effect of cumulative life
exposures on ALI risk following trauma; a major environmental
insult (trauma) is required to become at risk for ALI; and a recently
published study by our group found little difference between these
pediatric population controls and other adult controls [31].
We carried forward SNPs with p,0.01 for ALI association in
our discovery sample to a replication phase (Phase 2) [29]. The
replication population consisted of a nested case-control design of
212 ALI cases and 283 at-risk major trauma controls from ongoing
cohort studies at the five participating centers. At-risk controls
were defined as severely injured subjects with ISS.16 [32],
admitted to the intensive care unit who did not develop ALI
during hospital stay, and were primarily drawn from two sites
(HSPH and UW). We used logistic regression to adjust for
potential confounding clinical factors, including age, ISS, and
mechanism of trauma (classified as blunt or penetrating).
SNPs that achieved significance at p,0.05 level in our Phase 2
replication set were subject to functional evaluation using
expression quantitative trait loci (eQTL) analyses for cis-regulating
elements from B-LCL derived from 60 European ancestry and
Yoruban HapMap trios (mother, father, offspring) evaluated under
two conditions: stimulated with CL097, an innate immune agonist
acting through Toll-like receptor 7 (TLR7), or with culture media
alone [33]. Cis-acting eQTL in the setting of CL097-exposed B-
LCL were determined using a linear regression model in unrelated
individuals. Cis-tests were performed with SNPs (allele frequen-
cy.5%) mapping within 1 MB of the array probe start site. Cis
eQTL were confirmed in the parent-offspring trios using the
quantitative transmission-disequilibrium test (QTDT) [34], as
implemented in the QTDT software package (http://www.sph.
umich.edu/csg/abecasis/QTDT/index.html).
Genotyping Methods and Quality Control
We used the Illumina HumanQuad610 BeadChip (Illumina,
San Diego) to determine genotypes for 620,901 linkage disequi-
librium bin-tagging polymorphisms and copy number variation
(CNV) markers. Approximately 500 ng of genomic DNA from
peripheral blood samples was used for each subject. Each sample
was whole-genome amplified, fragmented, precipitated, and
Figure 1. Overview of study design. Abbreviations: ALI, acute lung
injury; eQTL, eQTL, expression quantitative trait loci.
doi:10.1371/journal.pone.0028268.g001
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hybridized on BeadChips for 16 hours at 48uC, the single base
extension reaction performed, and the chip stained and imaged on
an Illumina Bead Array Reader. Normalized intensity data for
each sample were loaded into Illumina Beadstudio 2.0 and
genotypes called using the manufacturer’s clustering algorithm.
Gender was checked using built-in controls. Clusters were checked
for separation, deviation from Hardy-Weinberg, and lack of
variation (mono-morphism). Genotypes that did not deviate from
Hardy-Weinberg Equilibrium, demonstrated .95% call rate, and
a minimum quality score determined by the manufacturer’s
software, were eligible for statistical association analyses. SNP
imputation was also performed on the discovery cohort using the
Markov Chain Haplotyping (MACH) software (http://www.sph.
umich.edu/csg/abecasis/MaCH/index.html) for genotype impu-
tation on markers that are not present in the genotyping platform
used. The software version 1.0.16 was used in the study, and the
default two-step procedure was adopted for imputation. The
software requires several input files for SNPs and phased
haplotypes, so we used the HapMap phased haplotypes (release
22) on HapMap Utah residents with ancestry from northern and
western Europe (CEU) subjects, as downloaded from the HapMap
database (http://www.hapmap.org). We analyzed the mlinfo file
generated from the imputation process and used the recom-
mended R
2 threshold of 0.3 to flag unreliable markers used in
imputation analysis, and removed these markers from association
tests. We also analyzed the mlqc file, which provides a per-
genotype posterior probability for each imputed call, and we used
the 0.9 threshold to flag unreliable calls (by recoding them as
NoCall genotype). In total, 2,487,415 imputed autosomal markers
(out of 2.54 million markers with phase information in HapMap
CEU population) passed quality control for the ALI cohort. We
have included all loci with p,0.01 in Phase 1 in Supplemental
Table S2.
Statistical Analysis
Statistical tests for genetic association were conducted using
PLINK [35]. To reduce the risk of population stratification due to
misspecification of self-reported ancestry, we screened all cases and
controls at ancestry informative markers (AIMs) using the
STRUCTURE software package and removed outliers from
principal components analysis. Using the methods of Skol [36] and
assuming an additive model, two-stage design, 800 cases, 2500
controls, and carrying forward SNPs with an association p,0.01
in an additive model to stage 2 with a replication alpha of 0.05,
we determined that we would have greater than 80% power for
both Stage 1 and replication analyses to detect a relative risk of
1.5 or greater for allele frequencies of 0.10 or greater. Power for
SNP detection in individual phases was less. Phase 1 with 600
cases and 2200 controls yielded greater than 80% power for a
detectable relative risk of 1.5 or greater at an alpha of 0.01 for
allele frequencies greater than 0.10 (detectable RR 1.9 for
p,5610
28). In Phase 2 we had 80% power to detect relative
risks of 1.8 or greater at alpha 0.05 for allele frequencies of
greater than 0.10.
Results
Sample flow of ALI cases is presented in Supplemental Figure
S1. Characteristics of the ALI case, population control, and at-risk
control populations are contained in Table 1. In Phase 1, the
mean age of the ALI cases was 45 years, 70% were male, 92% had
blunt trauma and the mean ISS was 27. The mean age of the
controls was 9 years and 57% were male. In Phase 2, age, gender,
ISS, and mechanism of trauma were similar between cases and
controls. Supplemental Table S1 presents subject characteristics
by site. Age, gender, and ISS were similar according to individual
sites within cases and controls.
Following QC and filtering, the genomic inflation factor for the
Phase 1 discovery set was 1.027, indicating minimal differences in
underlying population structure between cases and controls
(Figure 2). Figure 3 represents a Manhattan plot of 2log10(p-
value) in the Phase 1 discovery cohort. A total of 5815 genotyped
SNPs demonstrated association in the Phase 1 discovery cohort at
p,0.01; these SNPs were carried forward to the replication phase
(Phase 2). Supplemental Table S2 presents results of 28,618
imputed SNPs from Phase 1 that were associated with ALI at
p,0.01.
A total of 159 SNPs achieved p,0.05 in the Phase 2
replication set with similar direction of OR when adjusted for
age, gender, ISS, and mechanism of trauma (Supplemental Table
S3). Of note, several of these SNPS were in genes that could
plausibly be associated with mechanisms contributing to ALI
(Table 2), including members of the thrombospondin [37,38],
tetraspanin [39], and chitinase families [40,41]. One replicated
variant resulted in an amino acid substitution in the correspond-
ing gene product, a Leu29Ile substitution in CCL24 (or eotaxin-
2) [42].
Table 1. Demographics of Trauma ALI SNP Consortium (TASC) subjects.
Phase 1 (n=2866) Phase 2 (n=495)
Cases (n=600) Controls (n=2266) Cases (n=212) Controls (n=283)
Gender n=596
Males (%) 419 (70%) 1287 (57%) 158 (75%) 206 (73%)
Female (%) 177 (30%) 979 (43%) 54 (25%) 77 (27%)
Age in years n=589 n=2250 n=195 n=270
44.78 (620.05) 8.64 (65.72) 44.32 (619.66) 38.90 (620.76)
ISS n=542 n=194 n=266
26.97 (69.98) NA 27.77 (610.44) 23.94 (610.72)
Blunt Injury (%) n=528 n=180 n=173
488 (92%) NA 168 (93%) 149 (86%)
Abbreviations: ALI, acute lung injury; SNP, single nucleotide polymorphism; ISS, Injury Severity Score; NA, not applicable.
doi:10.1371/journal.pone.0028268.t001
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forward to functional evaluation in Phase 3. In eQTL analyses of
TLR-7 stimulated HAPMAP B-LCL, there was significant
differential expression of PPFIA1 mRNA (p=0.0021) according
to genotype of rs471931, a cis-acting SNP on 11q13.3 (Table 3).
The PPFIA1 gene encodes liprin alpha, a protein involved in cell
adhesion and cell-matrix interactions [43].
We additionally screened our discovery phase to test the
association of loci with prior reported association with ALI
(Table 4). Notably, the IL10 SNP (rs1800896 at 21082 in the
promoter region) showed a similar effect on ALI risk as in prior
reports [12]. However, as our GWA platform was not specifically
designed to provide adequate coverage for these loci of interest,
many of the previously associated SNPs in other genes were not
available. Therefore, we also report results for other SNPs within
the same candidate genes in Table 4. Several of these candidate
genes contained additional loci associated with ALI risk including
IL10, FAS [44], MYLK [45], and ANGTP2, although the specific
SNPs from prior publications did not replicate in the case of FAS
and MYLK.
Discussion
To our knowledge, this is the first genome wide association
study to examine the risk of ALI. We demonstrate association at
multiple loci in two independent datasets; when coupled to eQTL
analysis, the putatively functional results prioritize novel loci for
future ALI research. Furthermore, this study provides evidence of
feasibility for future GWAS in trauma and other at-risk
populations, including those using at-risk controls in the discovery
phase.
The putatively functional genetic variant identified in this study
suggests a compelling hypothesis to explain the pathogenesis of the
observed link with ALI risk. The protein encoded by the PPFIA1
gene is a member of the liprin (LAR protein-tyrosine phosphatase-
interacting protein) family [46]. Liprins have mostly been studied
in the nervous system and in mammary gland development [46];
however, liprin alpha binds to the intracellular membrane-distal
phosphatase domain of tyrosine phosphatase ‘leukocyte antigen
related’’ (LAR), and may regulate the disassembly of focal cell
adhesion, influencing cell-matrix interactions [47]. Liprin alpha
Figure 2. Quantile-Quantile (Q-Q) plot of single SNP association with ALI.
doi:10.1371/journal.pone.0028268.g002
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beta1 integrins [48]. Integrins are involved in the pathogenesis
ALI through interactions with the extracellular matrix, altering
cell adhesion and lung vascular permeability [49,50].
The exact function of the genetic regulation of rs471931 on the
PPFIA1 gene is not known. It is approximately 280Kb downstream
of PPFIA1 on 11q13.3 and there are intervening genes, including
SHANK2. Future studies may focus on fine mapping the region to
better understand the role of genetic regulation of liprin alpha
expression in ALI risk.
A novel feature of our study is the use of eQTL analyses that
employ transformed stimulated lymphocytic cell lines to evaluate
functional differences between the genotypes on our list, providing
evidence of differential expression according to our ALI-risk
Figure 3. Manhattan plot of 2log10(p-value) for SNP association with ALI.
doi:10.1371/journal.pone.0028268.g003















p Symbol Gene Name
Entrez
gene ID
5 rs2398611 0.65 0.0012 C 0.05 0.10 0.47 0.0061 ARHGAP26 Rho GTPase activating protein 26 23092
12 rs1468674 1.25 0.0014 G 0.53 0.46 1.33 0.0386 KLRB1 killer cell lectin-like receptor subfamily B, member 1 3820
5 rs248244 1.60 0.0015 T 0.08 0.05 1.83 0.0347 SQSTM1 sequestosome 1 8878
21 rs2838659 0.78 0.0032 G 0.21 0.25 0.70 0.0330 TSPEAR thrombospondin-type laminin G domain and EAR
repeats
54084
1 rs1321106 1.23 0.0036 C 0.37 0.31 1.41 0.0193 TSPAN2 tetraspanin 2 10100
12 rs2701129 0.69 0.0045 A 0.09 0.13 0.57 0.0179 NR4A1 nuclear receptor subfamily 4, group A, member 1 3164
14 rs847301 0.63 0.0051 T 0.03 0.07 0.47 0.0298 RGS6 regulator of G-protein signaling 6 9628
5 rs4546368 0.82 0.0053 T 0.41 0.47 0.75 0.0371 ABLIM3 actin binding LIM protein family, member 3 22885
7 rs7778918 0.81 0.0055 A 0.30 0.35 0.73 0.0498 THSD7A thrombospondin, type I, domain containing 7A 221981
10 rs1948837 1.56 0.0061 G 0.06 0.04 1.89 0.0447 PRKG1 protein kinase, cGMP-dependent, type I 5592
8 rs12547884 0.78 0.0068 A 0.18 0.26 0.66 0.0162 MSRA methionine sulfoxide reductase A 4482
7 rs2302006 0.78 0.0072 A 0.17 0.24 0.70 0.0463 CCL24 chemokine (C-C motif) ligand 24 6369
1 rs3820145 0.78 0.0084 A 0.17 0.23 0.62 0.0104 CHIT1 chitinase 1 1118
10 rs7922288 1.27 0.0086 C 0.20 0.15 1.47 0.0312 PTPRE protein tyrosine phosphatase, receptor type, E 5791
6 rs237012 1.20 0.0091 A 0.53 0.44 1.35 0.0389 TAB2 TGF-beta activated kinase 1/MAP3K7 binding protein 2 23118
10 rs1317790 1.38 0.0098 T 0.12 0.08 1.61 0.0444 MPP7 membrane protein, palmitoylated 7 143098
3 rs4553956 0.81 0.0101 T 0.22 0.28 0.70 0.0271 TP63 tumor protein p63 8626
8 rs8178179 1.42 0.0107 C 0.08 0.04 2.24 0.0110 PRKDC protein kinase, DNA-activated, catalytic polypeptide 5591
15 rs10520676 0.80 0.0101 G 0.18 0.24 0.64 0.0109 NTRK3 neurotrophic tyrosine kinase, receptor, type 3 4916
Abbreviations: Chr, chromosome; SNP, single nucleotide polymorphism; OR, odds ratio; Disc. or, odds ratio from phase 1 additive trend model; Disc. p, p value from
phase 1 additive trend model; maf, minor allele frequency; ali: acute lung injury; repl. or, or from phase 2 additive trend model; repl. p, p value from phase 2 additive
trend model.
doi:10.1371/journal.pone.0028268.t002
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differential expression exists in cell types that were not included
in our approach, such as in pneumocytes or macrophages [18].
Therefore, SNPs not found to have differential expression in our
functional phase could potentially have functional consequences in
other tissues and be linked to ALI risk. However, as of the time of
this publication there were no available datasets with both
genome-wide genotyping and genome-wide gene expression in
lung specific tissues to our knowledge. As such, we have presented
the results of association for the 159 SNPs replicating to nominally
significant p-values in Phase 2, as lack of functional correlation in
our study does not rule out a role in ALI risk.
Of replicated loci, several have hypothesized putative roles in
ALI pathogenesis, as presented in Table 2. In particular, members
of the thrombospondin and chitinase families [40,41] have been
implicated in ALI pathogenesis [37,38]. Tetraspanins have been
shown to influence lipopolysaccharide-induced macrophage acti-
vation and lung inflammation [39]. CD161 has recently been
implicated in regulating the tissue-homing and inflammatory
effects of T-cells, including IL-17 producing cells [51,52,53].
Methionine sulfoxide reductase A (MSRA) protects against
oxidative stress [54], and the TAB2 gene encodes a protein in
the IL-1 signal transduction pathway [55,56]. ARGAP26 encodes
Rho GTPase activating protein 26; and Rho family GTPases may
regulate endothelial barrier integrity through interactions with the
actin cytoskeleton [57]. Likewise, the protein product actin-
binding LIM 3 (abLIM3) has recently been described to affect
barrier integrity in bronchial epithelium through actin binding as a
component of the junctional complex [58].
One of our replicated loci resulted in an amino acid change in
the protein product CCL24. This encoded protein, also known as
eotaxin-2, has been involved in pulmonary allergic response [42],
and there is evidence of alteration of levels due to genetic variation
in humans [59]. Likewise, the potential functional consequence of
the specific IL10 SNP rs1800896 sets this promoter variant as a
priority for future studies of ALI. Of note, in the original
description by Gong, et al, an interaction was detected with
younger age, as is seen in the relatively young age of our trauma
study cohort [12]. In addition, although prior published SNPS did
not replicate, gene-based replication of prior FAS, ANGTP2, and
MYLK associations with ALI prioritize these candidate loci for
future study.
The use of population-based controls in the derivation stage
allowed for optimization of power while preserving at-risk trauma
controls for the replication stage. Although this approach is
efficient and economical, there may have been biases introduced
because the controls did not suffer the same predisposing risk
factor (major trauma), and were drawn from pediatric cohorts.
ALI only develops after a severe precipitating insult, and ALI
susceptibility genes may be quiescent unless a severe environmen-
tal insult occurs (e.g. sepsis, influenza, blood transfusion, or major
trauma) [60]. Therefore, it is possible that there are ALI
susceptibility genes that were not apparent in our discovery phase
(false negative results). Nonetheless, we do not believe our choice
of controls in Phase 1 would lead to false positive results for the
following reasons: a) none of our candidate genes are plausibly
linked with survival to the age of traumatic insult; b) the pediatric
population controls have been shown to be similar to adult
population controls; and c) and Phase 2 used at-risk nested
controls with major trauma that were followed for ALI
determination but did not develop the syndrome, thereby
minimizing selection bias. However, it is likely that a larger
discovery phase using at-risk trauma controls of similar age may
uncover additional risk variants. We estimate that 1000 cases and
at-risk controls would provide adequate power to detect genotype
relative risks greater than 1.6 for common variants, and larger
samples would be needed for uncommon variants.
Our study has several additional limitations. First, the discovery
sample set is on the lower bounds of power for demonstrating
GWAS significance [36,61]. Although we were powered to detect
common SNPs in a two-stage design, our replication sample was
modest; we may have missed important (and less common)
variants and therefore negative findings should be interpreted with
caution [16]. However, our three-stage genotyping approach with
functional characterization of the resulting association signals
should minimize the chances of our findings being false positive
associations. Likewise, for efficiency and economy, our discovery
phase used already-genotyped controls from a single site; therefore
confounding due to population stratification may have been
possible. However, our statistical approach yielded an excellent
genomic inflation factor, and our results replicated in subjects
taken from several sites in Phase 2, making population admixture
unlikely to bias our results. None of our SNPs achieved
significance in our derivation set at the genome-wide multiple
comparison level (p,5610
28). However, this should not be
interpreted as a lack of evidence of a genetic basis for ALI, given
the modest sample size, and given the positive results of our three-
stage study design [27]. We chose the trauma population to
minimize heterogeneity of ALI etiology and efficiently leverage
population-based controls in the Phase 1 discovery phase.
However, the pathophysiology of ALI following trauma may be
different than other at risk ALI populations [62], and therefore the
findings may not be generalizable to other causes of ALI. Future
studies will need to replicate our findings in other at-risk
populations.
As the first GWA in acute lung injury, our study has uncovered
an important novel variant regulating PPFIA1 expression to
prioritize for future studies. Furthermore, our study supports the
feasibility of using a multiple-staged GWAS approach in future
studies of ALI risk. Bench and translational research studies
focused on the roles of liprin alpha 1 in ALI pathogenesis seem
warranted. In addition, we have replicated a candidate gene with
prior ALI association as well as several genes in pathways with
evidence of a role in ALI pathogenesis to serve as priority
candidates for future study. Like other complex syndromes,
additional novel putative risk genes will likely be uncovered with
Table 3. Replicated SNP that alters expression in stimulated B-lymphoblastic cell lines (B-LCLs) [33].
CHR SNP
MAF











11 rs471931 0.50/0.45 1.20 0.0107 1.53 0.0045 PPFIA1 0.0021
Abbreviations: SNP, single nucleotide polymorphisms; Chr, chromosome; MAF, minor allele frequency; OR, odds ratio; mRNA, messenger ribonucleic acid; eQTL,
expression quantitative trait loci.
doi:10.1371/journal.pone.0028268.t003
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Gene Chr SNP Reference Candidate SNP Candidate Gene
F5 1 rs6025 (Arg506Gln) [63] N/A NS
IL10 1 rs1800896 (A/G 21082) [64] OR 1.15 p=0.039 rs1554286
OR 0.80
p=0.00498
IL1RN 2 rs4251961 [65] OR 1.02 p=0.80 NS
NFE2L2 2 rs1754059 (C/A 2617) [9] N/A NS
SFTPB 2 rs1130866 (T/C +1580) [66,67,68] OR 1.07 p=0.54 NS
MYLK 3 rs9840993 [6,45] N/A rs11718105
rs4678047 OR 0.93 p=0.33 OR 1.28
rs28497577 N/A p=0.00150




TLR1 4 rs5743551 (A/G 2720) [69] N/A NS
TNF 6 rs1800629 (G/A 2308) [70] OR 0.88 p=0.48 NS
VEGF 6 rs833061 (C/T 2460) [71,72] OR 1.09 p=0.39 NS
rs2010963 (C/G +405) N/A
rs3025039 (C/T +936) N/A
IL6 7 rs4800795 (G/C 2174) [73,74,75,76] OR 1.06 p=0.46 NS
PBEF1 7 rs41496055 [8] N/A NS
ANGPT2 8 rs2959811 [77,78] OR 0.89 p=0.10 rs7825407
rs2515475 OR1.00 p=0.97 OR 1.27
rs1868554 – imputed OR 1.22 P=0.00189
p=0.0083
FAS 10 rs2147420 - imputed [44] OR 0.99 p=0.86 rs9658691
rs2234978 - typed OR .93 p=0.30 OR 0.68
rs1051070 - imputed OR 1.02 p=0.96 p=0.00102
MBL2 10 rs1800451 [79,80,81] N/A NS
PLAU 10 rs1916341 [82] N/A NS
rs2227562 OR 1.02 p=0.88
rs2227564 OR 0.97 p=0.71
rs2227566 N/A
rs2227571 N/A
rs4065 OR 0.97 p=0.58
IRAK3 12 rs10506481 - imputed [83] OR 0.96 p=0.75 NS
NFKBIA 14 rs3138053 (A/G 2881) [84] OR 0.83 p=0.073 NS
rs2233406 (C/T 2826) N/A
rs2233409 (C/T 2297) N/A
HMOX2 16 rs1362626 [85] OR 0.99 p=0.87 NS
rs2404579 N/A
rs2270366 OR 1.03 p=0.70
rs1051308 OR 1.03 p=0.70
rs7702 OR 0.97 p=0.73
NQO1 16 rs689455 [86] N/A NS
FTL 19 rs905238 [85] OR 1.07 p=0.31 NS
rs918546 N/A
rs2230267 N/A
MIF 22 rs2070767 [87] N/A NS
rs755622 N/A
GWAS Identifies PPFIA1 as Candidate ALI Risk Gene
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Supporting Information
Figure S1 Schematic representation of the quality control
method employed. Of the total 1066 cases of ALI submitted for
analysis, 217 were excluded from further analyses due to evidence
of non-European ancestry. (Abbreviations: ALI, acute lung injury;
AIM, ancestry informative markers; PCA, principal components
analysis; Pre-QC EA pre-quality control; EA’ European-Ameri-
can; GWA, Genome Wide Association).
(TIF)
Table S1 Subjects Characteristics by site. (Abbreviations: ALI,
acute lung injury; SNP, single nucleotide polymorphism; ISS,
Injury Severity Score; NA, not applicable).
(DOCX)
Table S2 Imputed Phase 1 loci with p,0.01 for ALI association.
(Abbreviations: CHR, chromosome; SNP, single nucleotide
polymorphism; BP, base pair location; OR, odds ratio; ANNOT,
annotated locus).
(XLSX)
Table S3 Phase 2 SNPs with p,0.05 and consistent direction of
OR when adjusted for age, gender, injury severity score (ISS), and
mechanism of trauma. (Abbreviations: SNP, single nucleotide
polymorphism; BP, base pair location OR, odds ratio; Discover-
y_or_trend, odds ratio from phase 1 additive trend model;
Discovery_p_trend, p value from phase 1 additive trend model;
maf, minor allele frequency; ali: acute lung injury; replicatio-
n_or_trend, or from phase 2 additive trend model; replication_p_
trend, p value from phase 2 additive trend model; l95_trend, lower
bound of the confidence interval for or from phase 2 additive trend
model; u95_trend, upper bound of the confidence interval for or
from phase 2 additive trend model).
(XLS)
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